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Abstract
Background: The therapeutic use of autologously pre-
pared, platelet–leukocyte-enriched gel (PLG) is a rela-
tively new technology for the stimulation and
acceleration of soft tissue and bone healing. The eﬀec-
tiveness of this procedure lies in the delivery of a wide
range of platelet growth factors mimicking the physio-
logic wound healing and reparative tissue processes.
Despite an increase in PLG applications, the structures
and kinetics of this autogenously derived biologic
material have not been observed.
Methods: A review of the most recent literature was
performed to evaluate the use of PLG in various surgical
disciplines.
Results: The review showed that the application of PLG
has been extended to various surgical disciplines including
orthopedics, cardiac surgery, plastic and maxillofacial
surgery, and recently also endoscopic surgery.
Conclusion: This review demonstrates the usefulness of
PLG in a wide range of clinical applications for
improvement of healing after surgical procedures.
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Soft tissue wound healing and bone growth involve
physiologic cascades in which cellular and hormonal
factors play pivotal roles [1, 2]. Some of these cascade
components can be isolated from autologously drawn
whole blood. Point-of-care devices can intraoperatively
fractionate the autologous blood into platelet-poor
plasma, platelet–leukocyte-rich plasma (P-LRP), and
red blood cells [3, 4]. The P-LRP fraction, a mixture of
concentrated platelets and leukocytes, can be activated
by (autologous) thrombin to create a viscous solution
known as platelet–leukocyte gel (PLG). This platelet
coagulum can be exogenously applied to soft wound
tissues, bone, or synthetic bone as a spray or as a solid,
clotted, gelatinous mass. The rationale for applying
platelet gel is based on the delivery of platelet growth
factors to tissues and on the fact that platelet a-granules,
found inside the platelets, contain a variety of growth
factors [5]. Platelet gel growth factors are peptides that
promote cell proliferation, diﬀerentiation, chemotaxis,
and the migration of various cells involved in both
wound healing and bone growth [6, 7].
Recently, numerous P-LRP devices have become
available for therapeutic use to stimulate and accelerate
soft tissue and bone healing and to control postopera-
tive wound bleeding. The rationale for applying PLG
lies in the mimicking and accelerating of physiologic
wound healing and reparative tissue processes.
This article provides information on the results of
electron microscopic imaging used to evaluate the con-
tent of PLG. Furthermore, because the use of PLG is a
relatively new per- and/or perioperative biotechnologi-
cal application, new and additional indications for the
use of PLG are deﬁned. New PLG applications are re-
viewed for diﬀerent applications including cardiac sur-
gery, general surgery, orthopedics and traumatology,
cosmetic surgery, maxillofacial surgery, sports medicine,
and endoscopic surgical procedures.
Deﬁning platelet–leukocyte-rich gel
Platelet–leukocyte gel is prepared from a high concen-
tration of platelets acquired from freshly drawn autol-
ogous whole blood. In general, this blood is obtained byCorrespondence to: P. A. Everts
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point-of-care devices and sequestered into diﬀerent
blood components, namely, P-LRP, platelet-poor plas-
ma, and erythrocyte concentrate [8].
One characteristic of P-LRP is that it comprises a
small volume of plasma with ﬁbrinogen, platelets, and
leukocytes. Platelets suspended in the P-LRP are in an
inactive state and in liquid form. The platelet growth
factors are found inside a granules, which are present in
the platelet cytoplasm. Platelets become immediately
activated because of interaction with thrombin, the most
potent platelet activator, and a sticky platelet aggregate
is formed. Subsequently, platelet a granules release
growth factors into the extracellular environment, where
they bind to speciﬁc platelet growth factor receptors.
After this, through intracellular tissue signaling, a
number of pathways are triggered that initiate the
healing process.
Besides a high concentration of platelets in PLG,
several diﬀerentiated and nonactivated leukocytes are
present at high levels. In particular, these include neu-
trophilic granulocytes and monocytes, both known for
host defense mechanism actions against bacteria
through the action of myeloperoxidase that creates
hypochloric acid. The number of platelets in PLG is
three to seven times higher than normally found,
whereas the white blood cell count is two to four times
greater than normal [9–11].
Healing mechanisms of platelet–leukocyte gels
It is generally accepted that platelet growth factors play
a central role in the healing process and tissue formation
[12]. Wound healing is a well-orchestrated and complex
series of events involving cell–cell and cell–matrix
interactions, in which platelet growth factors serve as
messengers to regulate various processes. Initially, tissue
repair begins with platelet clot formation, activation of
the coagulation cascade and platelet degranulation, and
the release of growth factors. After this release, speciﬁc
platelet growth factors bind to particular target tyrosine
growth factor receptors, which subsequently activate
intracellular signal transduction pathways [7, 13].
During the ﬁrst 2 days of wound healing, an
inﬂammatory process is initiated by migration of neu-
trophils and subsequently macrophages to the wound
site. In turn, activated macrophages release multiple
growth factors, including platelet-derived growth factor,
transforming growth factors alpha and beta, interleu-
kin-1, and ﬁbroblast growth factor [11]. Angiogenesis
and ﬁbroplasia start shortly after day 3, followed by
collagen synthesis on days 3 to 5. This process leads to
an early increase in wound-breaking strength, which is
the most important wound-healing parameter of surgi-
cal wounds, followed by epithelialization and the ulti-
mate remodeling process [14].
Some functions of platelet growth factors in tissue
repair showed that a controlled sequential appearance is
crucial after primary wound closures at the end of sur-
gical procedures for the treatment of bone and cartilage
defects as well as muscle and tendon lesions, and for the
promotion of synthetic tissue ingrowth during recon-
structive surgeries [15].
Based on the actions of the various platelet growth
factors during the diﬀerent stages in the wound healing
cascade, the use of autologous PLG to stimulate wound
repair is an interesting proposition, although re-
combinant growth factors have been used to stimulate
wound healing. However, as compared with re-
combinant single growth factor applications, platelet
gels have the supreme advantage in that they synergis-
tically induce various growth factors and promote mi-
togenesis of mesenchymal stem cells at the wound site
[16, 17].
Novel platelet–leukocyte gel applications
After the activation of P-LRP with thrombin, a viscous
gel with a degree of plasticity is formed that sticks to
wound tissues. At this stage, PLG is exogenously ap-
plied, using a syringe delivery technique, to surgical
wound sites during closure and to soft tissue structures
to stimulate tissue regeneration (Fig. 1a and b), , or it is
mixed with bone or bone substitutes to accelerate bone
healing.
The outcome of multiple studies on the eﬃcacy of
PLG treatment have been published [18–20]. Proponents
of PLG application refer to improved wound healing
and increased bone growth to warrant its use. A
reduction in the development of severe postoperative
wound infections with the application of PLG during
incisional wound closure after a cardiac surgical proce-
dure has been reported [21]. These observations indicate
that this is a promising technique, with the result that
the delivery of autologous platelet growth factors and
vital neutrophilic leukocytes is now gaining more pop-
ularity. However, more scientiﬁc evidence and data to
support the use of PLG in clinical settings are manda-
tory for progress in the use of these autologous bio-
Fig. 1. Using a double-syringe delivery technique,
platelet–leucocyte gel is applied on the skin
wound of a patient with decubitis ulceration.
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technology procedures to be achieved. Recently, novel
applications have emerged in the ﬁeld of PLG applica-
tions and in a variety of surgical disciplines. We re-
viewed some of these new applications and report on
some results of studies that indicate some potentially
new directions and clinical applications.
Soft tissue healing and endoscopic applications
Promising results have been obtained for patients with
chronic nonhealing (diabetic) wounds after topical PLG
application. Margolis et al. [22] demonstrated that the
application of PLG was more eﬀective than standard
care methods for wound healing, and that this treatment
was even more eﬀective for patients with deeper wounds.
Furthermore, in our own experience we have encoun-
tered improved wound healing with the application of
PLG during wound closure after total knee arthroplasty
[23].
Soft tissue trauma such as tendon and ligament
ruptures and joint capsular injuries, which frequently
occur, often require a surgical intervention [24, 25]. It is
presumed that surgical repair combined with the appli-
cation of biologically active PLG should accelerate
healing with an improved outcome. Aspenberg and
Virchenko [26] showed, in an in vivo rat model, that
PLG applied to traumatized Achilles tendons increased
tensile strength and stiﬀness by about 30% after the ﬁrst
week. The eﬀect persisted for as long as 3 weeks after the
injection, suggesting that the use of PLG in tendon re-
pair improved the physiologic healing process.
Anterior cruciate reconstructive ligament surgery is
routinely performed to reconstruct the ligament with an
autologous graft. Because the procedure is mainly per-
formed arthroscopically, it is challenging to apply PLG
to augment healing. Sanchez et al. [27] reported en-
hanced healing with fewer complications and improved
ﬁxation of the graft within the bone tunnels in a retro-
spective clinical trial involving 100 patients.
The mechanism of action by which tendon repair is
improved with the application of PLG is based on re-
lease of vascular endothelial growth factor (VEGF).
This growth factor stimulates angiogenesis, leading to
an improved blood supply, which is mandatory for the
tendon repair process [28]. Furthermore, released
platelet growth factors induce a proliferation of tendon
cells and stimulate production of VEGF and hepatocyte
growth factor, a potent antiﬁbrotic agent. The latter
may be of importance in reducing scar formation and
ﬁbrosis in newly reconstructed tendon tissue, which may
lead to poor outcomes [29].
In the past, ﬁbrin glues have been used to make a
sutureless intestine anastomosis and to treat gastroin-
testinal anastomotic leaks during laparoscopic surgery
[30, 31].
Recently, a novel PLG application has emerged for
morbidly obese patients undergoing bariatric surgery.
Brady et al. [32] used PLG via an endoscopic delivery
system (Fig. 2), after a laparoscopic Roux-en Y gastric
bypass procedure to avoid hemorrhage, infection, and
anastomotic leaks, which may occasionally lead to
death. These authors suggest that the use of PLG con-
tributed to an enhanced hemostatic response, acceler-
ated tissue healing, and improved collagen synthesis,
thus preventing anastomotic leaks and thereby improv-
ing outcome. Recently, Pomerantz and Dutton [33] ap-
plied PLG during endoscopic sinus surgery to improve
their packing technique. Their quality-of-life scores
showed an improvement in terms of postoperative epi-
staxis, synechia formation, and exuberant granulation
tissue in PLG-treated patients.
Synthetic and allogeneic implants
Synthetic meshes and allogeneic implants are currently
used in ‘‘tension-free’’ hernioplasty of the abdominal
wall and in inguinal hernia repair [34]. However, after
cicatricial hernia repair, serious complications have been
observed (i.e., seromata, dense adhesions, ﬁstulization).
Furthermore, Tyrell et al. [35] observed that the tensile
strength of implanted meshes was markedly reduced due
to absorption of the mesh. Lichtenstein hernioplasty is
an accepted method for inguinal hernia repair. One of
the most frequent complications after inguinal hernia
surgery is postoperative pain, which at times is chronic
and permanent, leading to a poor quality of life [36, 37].
Innovative tools for decreasing the complication related
to anchoring of the mesh in position include the use of
tissue adhesives [38]. Another option for securing the
synthetic implants may be realized by applying PLG to
the meshes rather than to full suture lines. Autologous
platelet growth factors have been used by Zieren et al.
[39], who showed enhanced ingrowth and increased cell
proliferation with a higher number of ﬁbroblasts/colla-
gen ﬁbers in abdominal hernia repair, suggesting a role
of platelet growth factors in the healing process. Sclafani
et al. [40] showed an accelerated maturation of wounds
Fig. 2. Aerosol-controlled laparascopic platelet–leukocyte gel delivery
system.
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in an experimental setting when PLG was used. On the
basis of these ﬁndings, we have initiated a research
program to conﬁrm whether the application of PLG is
useful for hernia repair in a clinical setting. The study
objective is to determine the advantages of PLG use as
compared with current techniques, especially in mini-
mizing pain after conventional and laparoscopic her-
nioplasties.
Bone growth
Impaired bone healing after fractures, with the devel-
opment of pseudarthrosis, or fusion operations in the
case of nonunions cause pain and disability. Attempts
are being made to create bone substitutes, but technol-
ogies are being developed that improve bone healing by
adding biologic materials, such as PLG, to stimulate
osteogenesis and osteoconduction. In bone healing (i.e.,
callus formation), platelets act as an exogenous source
of growth factors stimulating the activity of bone cells
on the basis of a unique role in bone growth [41, 42].
Numerous in vitro studies using platelet gels have
been performed. Since the initial description of PLG use
in maxillofacial surgery, subsequent studies have fo-
cused on the eﬀect from a variety of bone-derived cells
including osteoblasts, osteoclasts, periodontal ligament
cells, and mesenchymal cells. Gruber et al. [43] demon-
strated that proliferation of bone-derived cells was
augmented, in a dose-dependent manner, when PLG
was used. They suggested that, aside from a mitogenic
eﬀect, PLG application at the time of surgery enhances
bone healing capacity due to bone resorption and
remodeling.
Another therapeutic application of PLG involves the
combination of PLG with diﬀerent bone substitutes.
Several authors have used histomorphometric analysis
to demonstrate a beneﬁcial eﬀect of PLG when diﬀerent
bone matrices are used. Aghaloo et al. [44] used natural
deproteinized bovine matrix and measured improved
bone growth when it was used with PLG. Suba et al. [45]
used b-tricalcium phosphate in combination with PLG
and observed more intense bone regeneration. Further-
more, due to the sticky structure of PLG, caused by the
ﬁbrin strands present in the gel, bone substitutes are
kept together, avoiding unwanted migration of bone
particles.
Recently, the percutaneous application of PLG in a
diabetic femur fracture model was described. Normal-
ized cellular proliferation and chondrogenesis, with im-
proved mechanical strength, were observed when PLG
was injected in this model [46].
Tissue engineering
A variety of methods have been used for the restoration
of bone or soft tissue defects in diﬀerent surgical set-
tings, including orthopedic surgery, maxillofacial sur-
gery, and reconstructive surgery [47, 48]. However, the
manipulation and reinforcement of biocompatible
materials in surgery is not always easy to achieve.
Mixtures of autologous tissues have been used to
accomplish restoration of defects. Tissue engineering, a
technology involving the morphogenesis of new tissues
using isolated cells with biocompatible matrices, often is
combined with growth factors. Mesenchymal stem cells
(MSC) are multipotent cells that can replicate as
undiﬀerentiated cells with the possibility of diﬀerenti-
ating into mesenchymal tissues (i.e., bone, cartilage,
tendon, muscle). This ability has made MSC a potential
component of tissue engineering concepts. Recently,
several research groups have been studying PLG as a
matrix for tissue-engineering models because the acti-
vated PLG releases numerous platelet-derived growth
factors [49, 50].
Another advantage of using MSC and PLG is that
these two components are autologous, nontoxic, and
biodegradable, proportional to the development of new
bone formation, as compared with allogeneic matrices,
which are nondegradable during the ﬁrst weeks after
implantation [51].
Yamada et al. [52] demonstrated in dogs that the
combination of MSC and PLG resulted in a signiﬁcantly
higher maturation of bone and neovasularization than
observed in control subjects. Thereafter, the same group
used a combination of MSC and PLG for successful
clinical alveolar bone augmentation [47]. The clinical
application of PLG with bone marrow–derived MSC
also was reported by Kito et al. [53] in the course of
distraction osteogenesis. In soft tissue engineering,
Anitua et al. [54] identiﬁed the role of PLG releasate on
cultured tendon cells. These authors state that the
treatment of tendon injuries may be of beneﬁt because
cell proliferation is induced with the promotion of
endogenous angiogenic growth factor synthesis.
Infection prevention
Many investigators have focused on the exogenous
application of concentrated and activated platelets in
PLG for a variety of procedures that result in the
material adhering to tissues, thereby initiating and
accelerating wound healing [17, 22]. However, in addi-
tion to the platelet gel delivery of growth factors, limited
data are available that address the role of leucocytes
present in PLG to act as an antimicrobial component
[10]. From our own experience, we have reported that P-
LRP not only comprises a high concentration of plate-
lets containing platelet growth factors, but that it also is
abundant in concentrated leukocytes, neutrophils,
monocytes, and lymphocytes [11]. Neutrophils and
monocytes are rich in granules containing myeloperox-
idase, which catalyzes the oxidation of chloride to gen-
erate hypochlorous acid and other reactive oxygen
derivates that act as potent bactericidal oxidants toxic to
microorganisms and fungi [55, 56].
Furthermore, Yeaman et al. [57] and Tang et al. [58]
support the idea that platelets also are involved in mi-
crobicidal activity, suggesting that they play a role in the
platelet host defense mechanism by releasing a variety of
platelet microbicidal proteins. The platelet microbicidal
proteins were shown to be released after platelet acti-
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vation, demonstrating potent activities against patho-
gens that have a tendency to enter the bloodstream [59].
Furthermore, we expect that exogenous PLG injec-
tions rather than periarticular injections with corticos-
teroids or even surgery will be indicated for the
treatment of tendonitis and periarthritis. Such a thera-
peutic approach was cautiously suggested in an equine
study that applied PLG to injured tendons [60].
Conclusion
Platelet–leukocyte gels may become an ideal autolo-
gously prepared biologic blood-derived product that can
be exogenously applied to a diversity of tissues, in which
it releases high concentrations of platelet growth factors
that enhance healing. In addition, it possesses antimi-
crobial properties that may contribute to the prevention
of infections.
The current review suggests that the use of PLG may
be beneﬁcial in surgery. Platelet–leukocyte gels have
been successfully used in maxillofacial surgery, ortho-
pedics, cosmetic surgery, and dental implantology.
However, the procedure for preparing PLG and the
techniques of application are likely to diﬀer greatly
among clinicians, resulting in inconsistent results. To
avoid conﬂicting data, standardization of P-LRP
methodology is therefore warranted. Furthermore,
randomized controlled clinical trials are needed to study
the eﬀect of PLG on wound rehabilitation, functional
recovery, and the promotion of bone growth. The bac-
tericidal eﬀect of PLG should be clariﬁed, and its role in
tissue engineering should be deﬁned. Overall, it may be
concluded that the structures present in PLG appear to
have a major beneﬁcial therapeutic eﬀect in surgery.
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